Loading...

SELLAS Life Sciences Group, Inc.

SLS•NASDAQ
Healthcare
Biotechnology
$2.17
$0.005(0.23%)

SELLAS Life Sciences Group, Inc. (SLS) Stock Overview

Explore SELLAS Life Sciences Group, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.6/100

Key Financials

Market Cap217M
P/E Ratio-6.75
EPS (TTM)$-0.36
ROE-1.94%
Fundamental Analysis

AI Price Forecasts

1 Week$1.74
1 Month$1.20
3 Months$1.23
1 Year Target$0.34

SLS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of SELLAS Life Sciences Group, Inc. (SLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 66.79, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.34.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -6.75 and a market capitalization of 217M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

66.79RSI (14)
0.15MACD
44.10ADX
Revenue Growth
0.00%
Profit Growth
$-0.31
↑ 17.30%
EPS Growth
$-0.31
↑ 66.33%
Operating Margin
0.00%
↑ 16.78%
ROE
-193.67%
↑ 17.30%
Dividend Yield
0.00%
Analyst Recommendations data is not available for SLSAnalyst Recommendations details for SLS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

CEO

Angelos M. Stergiou ScD h.c.

Employees

15

Headquarters

Times Square Tower, New York City, NY

Founded

2008

Frequently Asked Questions

;